Todd Golub

Affiliations: 
Pediatric Oncology Dana Farber Cancer Institute, Harvard Medical School 
Google:
"Todd Golub"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Krill-Burger JM, Dempster JM, Borah AA, et al. (2023) Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal. Genome Biology. 24: 192
Hoge ACH, Getz M, Zimmer A, et al. (2022) Publisher Correction: DNA-based copy number analysis confirms genomic evolution of PDX models. Npj Precision Oncology. 6: 50
Hoge ACH, Getz M, Zimmer A, et al. (2022) DNA-based copy number analysis confirms genomic evolution of PDX models. Npj Precision Oncology. 6: 30
Bondeson DP, Paolella BR, Asfaw A, et al. (2022) Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nature Cancer
Pagès M, Rotem D, Gydush G, et al. (2022) Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro-Oncology
Malone CF, Dharia NV, Kugener G, et al. (2021) Selective modulation of a pan-essential protein as a therapeutic strategy in cancer. Cancer Discovery
Dharia NV, Kugener G, Guenther LM, et al. (2021) A first-generation pediatric cancer dependency map. Nature Genetics
Prensner JR, Enache OM, Luria V, et al. (2021) Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nature Biotechnology
Cohen-Sharir Y, McFarland JM, Abdusamad M, et al. (2021) Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature
Corsello SM, Nagari RT, Spangler RD, et al. (2020) Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer. 1: 235-248
See more...